Craniocerebral metastases are a common site of metastasis in patients with advanced bronchopulmonary cancer. At this point, patients are deprived of surgery, and the usual treatment is control of the progression of the lung lesion and localized radiotherapy or local excision within the cranium.
If patients are not willing to undergo radiotherapy or surgery, they can use targeted therapy, and the third-generation targeted drug, oseltinib, is more effective for patients with advanced bronchopulmonary cancer with cranial metastases.